文献速递细菌感染、耐药与抗菌药物

多重耐药革兰阴性菌感染治疗的现状与未来展望

Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

本文综述多重耐药革兰阴性菌感染的治疗现状与未来方向,涉及AmpC酶、超广谱β-内酰胺酶和碳青霉烯酶等耐药机制,讨论新药、旧药及联合方案,并介绍在研新靶点。

要点

  • 革兰阴性菌耐药通过AmpC酶、超广谱β-内酰胺酶和碳青霉烯酶等机制全球播散。
  • 治疗依赖毒性较高的旧药与部分新药,疗效不一。
  • 新药、旧药再联合及在研新靶点是未来治疗方向。

核心结论

  • 多重耐药革兰阴性菌感染的治疗正结合旧药(多具高毒性)与新型药物,疗效程度不一,新靶点尚在研究中。

研究设计与样本

  • 本文为综述,讨论多重耐药革兰阴性菌的现有治疗、新药、旧药及两者新联合方案和在研新治疗靶点。

主要发现

  • 世界卫生组织优先耐药菌清单中三种被列为关键级别,均为革兰阴性菌。
  • 革兰阴性菌耐药通过多种机制全球传播,最棘手的是AmpC酶、超广谱β-内酰胺酶和碳青霉烯酶。
  • 旧药多具高毒性,与新型药物联合用于对抗多重耐药,成功率不一。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Microbial resistance is a serious threat to human health worldwide. Among the World Health Organisation's list of priority resistant bacteria, three are listed as critical-the highest level of concern-and all three are Gram-negative. Gram-negative resistance has spread worldwide via a variety of mechanisms, the most problematic being via AmpC enzymes, extended-spectrum β-lactamases, and carbapenemases. A combination of older drugs, many with high levels of toxicity, and newer agents are being used to combat multidrug resistance, with varying degrees of success. This review discusses the current treatments for multidrug-resistant Gram-negative bacteria, including new agents, older compounds, and new combinations of both, and some new treatment targets that are currently under investigation.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Bassetti M, Garau J. Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections. J Antimicrob Chemother. 2021. PMID: 34849997. doi:10.1093/jac/dkab352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。